Cargando…

Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy

OBJECTIVES: People with HIV-1 (PWH) on effective antiretroviral therapy (ART) continue to exhibit chronic systemic inflammation, immune activation, and persistent elevations in markers of HIV-1 infection [including HIV-DNA, cell-associated HIV-RNA (CA HIV-RNA), and antibodies to HIV-1 proteins] desp...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Kanal, Natarajan, Ven, Dewar, Robin, Rupert, Adam, Badralmaa, Yuden, Zhai, Tracey, Winchester, Nicole, Scrimieri, Francesca, Smith, Mindy, Davis, Ivery, Lallemand, Perrine, Giglietti, Aude, Hensien, Jack, Buerkert, Thomas, Goshu, Bruktawit, Rehm, Catherine A., Hu, Zonghui, Lane, H. Clifford, Imamichi, Hiromi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615727/
https://www.ncbi.nlm.nih.gov/pubmed/37555786
http://dx.doi.org/10.1097/QAD.0000000000003667
_version_ 1785129270031417344
author Singh, Kanal
Natarajan, Ven
Dewar, Robin
Rupert, Adam
Badralmaa, Yuden
Zhai, Tracey
Winchester, Nicole
Scrimieri, Francesca
Smith, Mindy
Davis, Ivery
Lallemand, Perrine
Giglietti, Aude
Hensien, Jack
Buerkert, Thomas
Goshu, Bruktawit
Rehm, Catherine A.
Hu, Zonghui
Lane, H. Clifford
Imamichi, Hiromi
author_facet Singh, Kanal
Natarajan, Ven
Dewar, Robin
Rupert, Adam
Badralmaa, Yuden
Zhai, Tracey
Winchester, Nicole
Scrimieri, Francesca
Smith, Mindy
Davis, Ivery
Lallemand, Perrine
Giglietti, Aude
Hensien, Jack
Buerkert, Thomas
Goshu, Bruktawit
Rehm, Catherine A.
Hu, Zonghui
Lane, H. Clifford
Imamichi, Hiromi
author_sort Singh, Kanal
collection PubMed
description OBJECTIVES: People with HIV-1 (PWH) on effective antiretroviral therapy (ART) continue to exhibit chronic systemic inflammation, immune activation, and persistent elevations in markers of HIV-1 infection [including HIV-DNA, cell-associated HIV-RNA (CA HIV-RNA), and antibodies to HIV-1 proteins] despite prolonged suppression of plasma HIV-RNA levels less than 50 copies/ml. Here, we investigated the hypothesis that nonreplicating but transcriptionally and translationally competent ‘defective’ HIV-1 proviruses may be one of drivers of these phenomena. DESIGN: A combined cohort of 23 viremic and virologically suppressed individuals on ART were studied. METHODS: HIV-DNA, CA HIV-RNA, western blot score (measure of anti-HIV-1 antibodies as a surrogate for viral protein expression in vivo), and key biomarkers of inflammation and coagulation (IL-6, hsCRP, TNF-alpha, tissue factor, and D-dimer) were measured in peripheral blood and analyzed using a combined cross-sectional and longitudinal approaches. Sequences of HIV-DNA and CA HIV-RNA obtained via 5′-LTR-to-3′-LTR PCR and single-genome sequencing were also analyzed. RESULTS: We observed similar long-term persistence of multiple, unique, transcriptionally active ‘defective’ HIV-1 provirus clones (average: 11 years., range: 4–20 years) and antibody responses against HIV-1 viral proteins among all ART-treated participants evaluated. A direct correlation was observed between the magnitude of HIV-1 western blot score and the levels of transcription of ‘defective’ HIV-1 proviruses (r = 0.73, P < 0.01). Additional correlations were noted between total CD8(+) T-cell counts and HIV-DNA (r = 0.52, P = 0.01) or CA HIV-RNA (r = 0.65, P < 0.01). CONCLUSION: These findings suggest a novel interplay between transcription and translation of ‘defective’ HIV-1 proviruses and the persistent immune activation seen in the setting of treated chronic HIV-1 infection.
format Online
Article
Text
id pubmed-10615727
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106157272023-11-03 Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy Singh, Kanal Natarajan, Ven Dewar, Robin Rupert, Adam Badralmaa, Yuden Zhai, Tracey Winchester, Nicole Scrimieri, Francesca Smith, Mindy Davis, Ivery Lallemand, Perrine Giglietti, Aude Hensien, Jack Buerkert, Thomas Goshu, Bruktawit Rehm, Catherine A. Hu, Zonghui Lane, H. Clifford Imamichi, Hiromi AIDS Basic Science OBJECTIVES: People with HIV-1 (PWH) on effective antiretroviral therapy (ART) continue to exhibit chronic systemic inflammation, immune activation, and persistent elevations in markers of HIV-1 infection [including HIV-DNA, cell-associated HIV-RNA (CA HIV-RNA), and antibodies to HIV-1 proteins] despite prolonged suppression of plasma HIV-RNA levels less than 50 copies/ml. Here, we investigated the hypothesis that nonreplicating but transcriptionally and translationally competent ‘defective’ HIV-1 proviruses may be one of drivers of these phenomena. DESIGN: A combined cohort of 23 viremic and virologically suppressed individuals on ART were studied. METHODS: HIV-DNA, CA HIV-RNA, western blot score (measure of anti-HIV-1 antibodies as a surrogate for viral protein expression in vivo), and key biomarkers of inflammation and coagulation (IL-6, hsCRP, TNF-alpha, tissue factor, and D-dimer) were measured in peripheral blood and analyzed using a combined cross-sectional and longitudinal approaches. Sequences of HIV-DNA and CA HIV-RNA obtained via 5′-LTR-to-3′-LTR PCR and single-genome sequencing were also analyzed. RESULTS: We observed similar long-term persistence of multiple, unique, transcriptionally active ‘defective’ HIV-1 provirus clones (average: 11 years., range: 4–20 years) and antibody responses against HIV-1 viral proteins among all ART-treated participants evaluated. A direct correlation was observed between the magnitude of HIV-1 western blot score and the levels of transcription of ‘defective’ HIV-1 proviruses (r = 0.73, P < 0.01). Additional correlations were noted between total CD8(+) T-cell counts and HIV-DNA (r = 0.52, P = 0.01) or CA HIV-RNA (r = 0.65, P < 0.01). CONCLUSION: These findings suggest a novel interplay between transcription and translation of ‘defective’ HIV-1 proviruses and the persistent immune activation seen in the setting of treated chronic HIV-1 infection. Lippincott Williams & Wilkins 2023-11-15 2023-08-22 /pmc/articles/PMC10615727/ /pubmed/37555786 http://dx.doi.org/10.1097/QAD.0000000000003667 Text en Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
spellingShingle Basic Science
Singh, Kanal
Natarajan, Ven
Dewar, Robin
Rupert, Adam
Badralmaa, Yuden
Zhai, Tracey
Winchester, Nicole
Scrimieri, Francesca
Smith, Mindy
Davis, Ivery
Lallemand, Perrine
Giglietti, Aude
Hensien, Jack
Buerkert, Thomas
Goshu, Bruktawit
Rehm, Catherine A.
Hu, Zonghui
Lane, H. Clifford
Imamichi, Hiromi
Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy
title Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy
title_full Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy
title_fullStr Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy
title_full_unstemmed Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy
title_short Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy
title_sort long-term persistence of transcriptionally active ‘defective’ hiv-1 proviruses: implications for persistent immune activation during antiretroviral therapy
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615727/
https://www.ncbi.nlm.nih.gov/pubmed/37555786
http://dx.doi.org/10.1097/QAD.0000000000003667
work_keys_str_mv AT singhkanal longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT natarajanven longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT dewarrobin longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT rupertadam longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT badralmaayuden longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT zhaitracey longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT winchesternicole longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT scrimierifrancesca longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT smithmindy longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT davisivery longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT lallemandperrine longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT gigliettiaude longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT hensienjack longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT buerkertthomas longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT goshubruktawit longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT rehmcatherinea longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT huzonghui longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT lanehclifford longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy
AT imamichihiromi longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy